{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:36:16Z","timestamp":1759178176378},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,9,10]],"date-time":"2011-09-10T00:00:00Z","timestamp":1315612800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1007\/s00280-011-1735-4","type":"journal-article","created":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T09:11:19Z","timestamp":1315559479000},"page":"1347-1353","source":"Crossref","is-referenced-by-count":9,"title":["A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy"],"prefix":"10.1007","volume":"68","author":[{"given":"S.","family":"Pignata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Amant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Sorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Breda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Rasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Hernes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Leunen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Cannella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,9,10]]},"reference":[{"issue":"Suppl 1","key":"1735_CR1","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/S0020-7292(06)60033-7","volume":"95","author":"AP Heintz","year":"2006","unstructured":"Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT et al (2006) Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S161\u2013S192","journal-title":"Int J Gynaecol Obstet"},{"key":"1735_CR2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0029-7844(98)00334-2","volume":"93","author":"SC Rubin","year":"1999","unstructured":"Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ (1999) Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 93:21\u201324","journal-title":"Obstet Gynecol"},{"key":"1735_CR3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.canlet.2011.01.026","volume":"303","author":"S Pignata","year":"2011","unstructured":"Pignata S, Cannella L, Leopardo D, Pisano C, Bruni GS, Facchini G (2011) Chemotherapy in epithelial ovarian cancer. Cancer Lett 303:73\u201383","journal-title":"Cancer Lett"},{"key":"1735_CR4","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D et al (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312\u20133322","journal-title":"J Clin Oncol"},{"key":"1735_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","volume":"95","author":"AN Gordon","year":"2004","unstructured":"Gordon AN, Tonda M, Sun S et al (2004) Long term survival advantage for women treated with pegylated liposomal doxorubicin versus topotecan in a phase III randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95:1\u20138","journal-title":"Gynecol Oncol"},{"key":"1735_CR6","doi-asserted-by":"crossref","unstructured":"Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, Richter B, L\u00fcck HJ, Kimmig R, Pfisterer J (2009) Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12\u00a0months following 1st-line platinum\/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie ovarian cancer study group (AGO-OVAR). Gynecol Oncol 114:199\u2013205","DOI":"10.1016\/j.ygyno.2009.04.026"},{"key":"1735_CR7","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1517\/14656566.7.8.975","volume":"7","author":"D Pectasides","year":"2006","unstructured":"Pectasides D, Psyrri A, Pectasides M et al (2006) Optimal therapy for platinum resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan? Expert Opin Pharmacother 7:975\u2013987","journal-title":"Expert Opin Pharmacother"},{"key":"1735_CR8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2005.04.018","volume":"98","author":"G Ferrandina","year":"2005","unstructured":"Ferrandina G, Paris I, Ludovisi M et al (2005) Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival. Gynecol Oncol 98:267\u2013273","journal-title":"Gynecol Oncol"},{"key":"1735_CR9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1006\/gyno.2001.6272","volume":"82","author":"PG Rose","year":"2001","unstructured":"Rose PG, Maxson JH, Fusco N et al (2001) Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol 82:323\u2013328","journal-title":"Gynecol Oncol"},{"key":"1735_CR10","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","volume":"26","author":"G Ferrandina","year":"2008","unstructured":"Ferrandina G, Ludovisi M, Lorusso D et al (2008) Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 26:890\u2013896","journal-title":"J Clin Oncol"},{"key":"1735_CR11","doi-asserted-by":"crossref","unstructured":"Armstrong D (2002) Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7(Suppl 5):20\u201328","DOI":"10.1634\/theoncologist.7-suppl_5-20"},{"key":"1735_CR12","first-page":"253","volume":"2","author":"BJ Bolwell","year":"1988","unstructured":"Bolwell BJ, Cassileth PA, Gale RP (1988) High dose cytarabine: a review. Leukaemia 2:253\u2013260","journal-title":"Leukaemia"},{"key":"1735_CR13","first-page":"50","volume":"20","author":"W Plunkett","year":"1993","unstructured":"Plunkett W, Gandhi V (1993) Cellular pharmacodynamics of anticancer drugs. Semin Oncol 20:50\u201363","journal-title":"Semin Oncol"},{"key":"1735_CR14","doi-asserted-by":"crossref","unstructured":"Rustum YM, Raymakers RA (1992) 1-Beta-arabinofuranosylcytosine in therapy of leukaemia: preclinical and clinical overview. Pharmacol Ther 56:307\u2013321","DOI":"10.1016\/0163-7258(92)90022-R"},{"key":"1735_CR15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0065-230X(08)60703-4","volume":"72","author":"S Grant","year":"1998","unstructured":"Grant S (1998) Ara-C: cellular and molecular pharmacology. Adv Cancer Res 72:197\u2013233","journal-title":"Adv Cancer Res"},{"key":"1735_CR16","first-page":"93","volume":"7","author":"S Gailani","year":"1976","unstructured":"Gailani S, Nussbaum A (1976) Correlation of response to 1-beta- D-arabinofuranosyl cytosine and metabolism of drug by tumour. J Med 7:93\u2013102","journal-title":"J Med"},{"key":"1735_CR17","unstructured":"Bajetta E, Verusio C, Bonfante V, Bonadonna G (1986) Cytarabine and cisplatin in advanced malignant melanoma. Cancer Treat Rep 70:1441\u20131442"},{"key":"1735_CR18","first-page":"365","volume-title":"Cancer: principles and practice of oncology","author":"BA Chabner","year":"1993","unstructured":"Chabner BA (1993) Anticancer drugs. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 4th edn. JB Lippincott Co, Philadelphia, pp 365\u2013369","edition":"4"},{"key":"1735_CR19","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s00280-005-0126-0","volume":"57","author":"H Someya","year":"2006","unstructured":"Someya H, Waud WR, Parker WB (2006) Long intracellular retention of 4\u2032-thio-arabinofuranosylcytosine 5\u2032-triphosphate as a critical factor for the antisolid tumour activity of 4\u2032-thioarabinofuranosylcytosine. Cancer Chemother Pharmacol 57:772\u2013780","journal-title":"Cancer Chemother Pharmacol"},{"key":"1735_CR20","unstructured":"Breist\u00f8l K, Balzarini J, Sandvold ML, Myhren F, Martinsen M, De Clercq F et al. (1999) Antitumour activity of P-4055 (Elaidic Acid-Cytarabine) compared to cytarabine in metastatic and s.c. human tumour xenograft models. Cancer Res 59:2944\u20132949"},{"key":"1735_CR21","first-page":"2658","volume":"50","author":"DD Ross","year":"1990","unstructured":"Ross DD, Chen SR, Cuddy DP (1990) Effects of 1-beta-Darabinofuranosylcytosine on DNA replication intermediates monitored by PH-step alkaline elution. Cancer Res 50:2658\u20132666","journal-title":"Cancer Res"},{"key":"1735_CR22","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.bcp.2003.09.028","volume":"67","author":"AM Bergman","year":"2004","unstructured":"Bergman AM, Kuiper CM, Voorn DA, Comijn EM, Myhren F, Sandvold ML et al (2004) Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukaemia and solid tumour cell lines. Biochem Pharmacol 67:503\u2013511","journal-title":"Biochem Pharmacol"},{"key":"1735_CR23","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1081\/NCN-200027735","volume":"23","author":"AM Bergman","year":"2004","unstructured":"Bergman AM, Kuiper CM, Myhren F, Sandvold ML, Hendriks HR, Peters GJ (2004) Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinosylcytosine (ara-C) in leukaemia and solid tumour cell lines. Nucleosides Nucleotides Nucleic Acids 23:1523\u20131526","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"1735_CR24","unstructured":"Dueland S, Aamdal S, Lind MJ, Thomas H, Sandvold ML, Gaullier JM, Rasch W (2009) Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A phase I study. Acta Oncol 48(1):137\u2013145"},{"key":"1735_CR25","doi-asserted-by":"crossref","unstructured":"Delaunoit T, Raymond E, Awada A, Savinelli F, Culine S, Rasch W et al. (2006) A three schedule phase I trial of CP-4055, weekly and q2\u00a0weeks in patients with advanced or metastatic solid tumours. J Clin Oncol (Suppl):267 (abstract)","DOI":"10.1200\/jco.2006.24.18_suppl.2067"},{"key":"1735_CR26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1735-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-011-1735-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1735-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T08:51:39Z","timestamp":1592902299000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-011-1735-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,10]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["1735"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1735-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2011,9,10]]}}}